Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Conditions: Relapsed or Refractory Non-Hodgkin ' s Lymphoma; Relapsed or Refractory Multiple Myeloma Interventions: Drug: BEBT-908 for injection Sponsors: BeBetter Med Inc Completed

https://clinicaltrials.gov/study/NCT06082596

Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials